ArticleJHLT open2026
Medium-term comprehensive outcomes of heart transplantation using donors with hepatitis C viremia to aviremic recipients.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although direct-acting antiviral (DAA) therapy has enabled successful use of organs from donors with hepatitis C (HCV) with favorable initial results, medium-term outcome data remains insufficient. This study aimed to compare 4-year mortality, primary graft dysfunction, and major adverse cardiac events (MACE) between heart transplants from donors with hepatitis C viremia (D+) and donors without hepatitis C viremia (D-) in aviremic recipients. Medium-term complications, including incidence of rejection, coronary artery vasculopathy (CAV), fibrosing cholestatic hepatitis (FCH), and extrahepatic manifestations of HCV, were also investigated. Methods: This retrospective cohort study included 256 (23 D+ and 233 D-) heart transplant recipients at a single institution between 2018 and 2022. Results: Over a 4-year follow-up period, survival was similar between D+ and D- recipients (91.3% [21/23] vs 89.3% [208/233], Conclusion: Patient and graft survival rates do not differ between D+ and D- heart transplant recipients. There is no difference in post-transplant complications, including MACE, rejection, CAV, FCH, and extrahepatic manifestations of HCV. These findings suggest medium-term safety in utilizing D+ hearts for enlarging the pool of limited organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.